A pilot open-label study of the efficacy of subanesthetic isomeric S(+)-ketamine in refractory CRPS patients

Pain Medicine

Volumn 9, Issue 1, 2008, Pages 44-54

  Kiefer, Ralph Thomas ^a   Rohr, Peter ^b   Ploppa, Annette ^a   Nohé, Boris ^a   Dieterich, Hans Jürgen ^a   Grothusen, John ^c   Altemeyer, Karl Heinz ^b   Unertl, Klaus ^a   Schwartzman, Robert J ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c DREXEL UNIVERSITY   (United States)

Author keywords

CRPS; NMDA Antagonists; Quantitative Sensory Testing; S(+) Ketamine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CLONIDINE; DIMETHYL SULFOXIDE; KETAMINE; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SODIUM CHANNEL BLOCKING AGENT; SPASMOLYTIC AGENT;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; BLURRED VISION; CASE REPORT; CLINICAL FEATURE; COMPLEX REGIONAL PAIN SYNDROME; CONTINUOUS INFUSION; DISEASE DURATION; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EUPHORIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEARTBURN; HUMAN; INSOMNIA; MECHANORECEPTOR; MOTOR DYSFUNCTION; NAUSEA; NIGHTMARE; PAIN ASSESSMENT; PAIN PARAMETERS; PAIN THRESHOLD; PHYSIOTHERAPY; SENSORY SYSTEM EXAMINATION; SIDE EFFECT; SWELLING; SYNCOPE; TINNITUS; VISUAL ANALOG SCALE; WEAKNESS;

ADOLESCENT; ADULT; ANESTHETICS, DISSOCIATIVE; COMPLEX REGIONAL PAIN SYNDROMES; DRUG RESISTANCE; FEMALE; HUMANS; KETAMINE; MALE; MECHANORECEPTORS; PAIN MEASUREMENT; PAIN THRESHOLD; PILOT PROJECTS; PROSPECTIVE STUDIES; SENSORY THRESHOLDS; STEREOISOMERISM; TEMPERATURE SENSE;

EID: 38949087896     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00223.x     Document Type: Article

References (41)

1. Stanton-Hicks M, Baron R, Boas R, et al. Complex regional pain syndromes: Guidelines for therapy. Clin J Pain 1998;14:155-66.
2. Schwartzman RJ, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep 2002;4:165-9.
3. Maleki J, LeBel A, Bennett GJ, Schwartzman RJ. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain 2000;88:259-66.
4. Baron R. Can we model CRPS type I? Pain 2004; 112: 8-9.
5. Jänig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. Clin Auton Res 2002;12(3):150-64.
6. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-8.
7. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth Analg 2003;97:1108-16.
8. Hocking G, Cousins MJ. Ketamine in chronic pain management: An evidence based review. Anesth Analg 2003;97:1730-9.
9. Takahashi H, Miyazaki M, Nanbu T, Yanagida H, Morita S. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a case. Pain 1998;75:391-4.
10. Lin TC, Wong CS, Chen FC, Lin SY, Ho ST. Long term epidural ketamine, morphine and bupivacaine attenuate reflex sympathetic dystrophy neuralgia. Can J Anaesth 1998;45:175-7.
11. Ushida T, Tani T, Kanbara T, et al. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. Reg Anesth Pain Med 2002;27:524-8.
12. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: A retrospective analysis of a novel approach to complex regional pain syndrome. Pain Med 2004;5:263-75.
13. Schüttler J, Zsigmond EK, White PF. Ketamine and its isomers. In: White PF, ed. Textbook of Intravenous Anesthesia, 1st edition. Philadelphia, PA: Williams & Wilkins; 1997:171-88.
14. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain 1999;81:147-54.
15. Jevtovic-Todorovic V, Wozniak DF, Powell S, Nardi A, Olney JW. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res 1998;781:202-11.
16. Fruhstorfer H, Gross W, Selbmann O. Technical note: Von Frey hairs: New materials for a new design. Eur J Pain 2001;5:341-2.
17. Treede RD, Rolke R, Andrews K, Magerl W. Pain elicited by blunt pressure: Neurobiological basis and clinical relevance. Pain 2002;98:235-40.
18. Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA. Heat pain thresholds: Normative data and repeatability. Pain 1995;60:329-32.
19. Ziegler EA, Magerl W, Meyer RA, Treede R-D. Secondary hyperalgesia to punctate mechanical stimuli: Central sensitization to A-fibre nociceptor input. Brain 1999;122:2245-57.
20. Maier C, Dertwinkel R, Mansurian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-Results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-83.
21. Wiech K, Kiefer RT, Töpfner S, et al. A placebo-controlled randomized cross-over trial of the NMDA receptor antagonist memantine in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-13.
22. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: A randomized, double-blinded, cross-over study. Anesth Analg 2000;91:960-6.
23. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology 2002;96:1053-61.
24. Gilron I, Booher SL, Rowan MS, Smoller MS, Max MB. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology 2000;55(7):964-71.
25. Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36.
26. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48(5):1212-8.
27. Persson J, Hasselstrom J, Wiklund B, etal. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand 1998;42:750-8.
28. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-52.
29. Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91(1-2):177-87.
30. Kiefer RT, Wiech K, Topfner S, Unertl K, Birbaumer N. Continuous brachial plexus analgesia and NMDA-receptor blockade in early phantom limb pain: A report of two cases. Pain Med 2002;3:156-60.
31. Kiefer RT, Wiech K, Dieterich HJ, Birbaumer N, Unertl K. The NMDA-receptor antagonist memantine for prevention and therapy of phantom limb pain. Anesthesiology 2003;A:1009.
32. Dertwinkel R, Heinrichs C, Senne I, et al. Prevention of severe phantom limb pain by perioperative administration of ketamine-Results of a pilot study. Acute Pain 2002;4:12-6.
33. Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain 2001;91:101-9.
34. Ilkjaer S, Dirks J, Brennum J, Wernberg M, Dahl JB. Effect of systemic N-methyl-D-aspartate receptor antagonist (dextromethorphan) on primary and secondary hyperalgesia in humans. Br J Anaesth 1997;79:600-5.
35. Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177-87.
36. Kiefer RT, Rohr P, Ploppa A, Unertl K, Schwartzman RJ. Ketamine in anesthetic dosage as treatment option for complex regional pain syndrome (CRPS) refractory to conventional treatment modalities. Anesthesiology 2005;103:A992.
37. Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Ikonomidou C. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 2002;12(4):488-98.
38. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001;895:264-7.
39. Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br J Pharmacol 2000;130(7):1692-8.
40. Himmelseher S, Durieux ME. Revising a dogma: Ketamine for patients with neurological injury. Anesth Analg 2005;101:524-34.
41. Bourgoin A, Albanese J, Wereszczynski N, et al. Safety of sedation with ketamine in severe head injury patients: Comparison with sufentanil. Crit Care Med 2003;31(3):711-7.